精华制药(002349) - 2024 Q3 - 季度财报

Financial Performance - Q3 2024 revenue reached ¥324,863,232.05, a slight increase of 0.17% year-over-year, while year-to-date revenue decreased by 6.65% to ¥1,045,172,312.93[2] - Net profit attributable to shareholders for Q3 2024 was ¥28,799,911.32, down 29.31% compared to the same period last year, with a year-to-date decline of 15.93% to ¥164,234,071.15[2] - Basic earnings per share for Q3 2024 was ¥0.0354, reflecting a decrease of 29.20% year-over-year, with year-to-date earnings per share at ¥0.2017, down 15.92%[2] - Total operating revenue for Q3 2024 was CNY 1,045,172,312.93, a decrease of 6.64% compared to CNY 1,119,659,192.47 in the same period last year[14] - Total operating profit for Q3 2024 was approximately CNY 228.94 million, a decrease of 11.0% compared to CNY 257.05 million in Q3 2023[15] - Net profit attributable to shareholders of the parent company was CNY 164.23 million, down 16.0% from CNY 195.35 million in the same period last year[15] - The total profit for Q3 2024 was CNY 225.21 million, a decrease of 12.3% from CNY 257.00 million in the same quarter last year[15] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥3,225,786,732.90, representing a 1.28% increase from the end of the previous year[2] - The company’s total liabilities decreased to CNY 324,604,048.05 from CNY 380,746,462.33, a reduction of 14.77%[12] - The total equity attributable to shareholders increased to CNY 2,535,754,992.57 from CNY 2,444,593,197.18, marking a growth of 3.76%[13] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥182,850,167.68, down 6.68% compared to the previous year[2] - Cash inflow from investment activities was CNY 710.86 million, significantly up from CNY 158.90 million in the previous year[16] - Cash flow from financing activities resulted in a net outflow of CNY 102.69 million, compared to a net outflow of CNY 92.66 million in Q3 2023[17] - The company reported a total cash and cash equivalents balance of CNY 1.30 billion at the end of Q3 2024, an increase from CNY 835.57 million at the end of Q3 2023[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 113,299[8] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 34.39% of the shares, totaling 279,994,660 shares[8] - The second-largest shareholder, Jiangsu Nantong Port Development Co., Ltd., holds 3.66% of the shares, totaling 29,826,020 shares[8] - The top ten shareholders include various institutional investors, with the Southern CSI 1000 ETF holding 0.83% of the shares, totaling 6,751,400 shares[9] - The company reported changes in the top ten shareholders due to securities lending activities, with no significant changes in ownership percentages[10] Research and Development - Research and development expenses for Q3 2024 were CNY 47,149,976.95, an increase from CNY 44,544,568.46 in the previous year, reflecting a focus on innovation[14] - The company plans to continue focusing on R&D and market expansion strategies to enhance future performance[2] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[14] Other Financial Metrics - Non-operating income for Q3 2024 included government subsidies of ¥212,130.66 and fair value changes of financial assets totaling ¥1,227,878.13[3] - The company reported a significant decrease in financial expenses by 57.77% year-over-year, attributed to increased deposit income[6] - The company experienced a 320.87% increase in cash recovered from investments, totaling ¥656,137,829.10 year-to-date[6] - Cash received from borrowings decreased to 10,000,000.00, a 37.50% decline compared to the same period last year, attributed to reduced bank borrowings by subsidiaries[7] - The impact of exchange rate fluctuations on cash and cash equivalents was -509,977.64, a 117.47% decrease due to foreign currency exchange rate changes during the reporting period[7]